Q-omics provides the consensus-scored ALKBH8 profile across patient tissues and cancer cell-line models. ALKBH8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ALKBH8 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ALKBH8 RNA expression shows 20,264 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, THCA, and ACC as cancer lineages where ALKBH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALKBH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALKBH8 survival associations across molecular data types. ALKBH8 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALKBH8 RNA expression–survival associations across cancer types. High ALKBH8 expression shows unfavorable associations in ACC, LGG and CESC, but favorable associations in UCS, KIRC and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for ALKBH8 RNA expression.
This table summarizes ALKBH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ALKBH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALKBH8 shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, LIHC, STAD and CHOL. The THCA box plot shows higher ALKBH8 RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with ALKBH8 in patient tissues and cancer cell lines. In patient samples, ALKBH8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ALKBH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
